Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06286007Recruiting

Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control

Role: collaborator

NCT04666116Not ApplicableUnknown

Changes in Viral Load in COVID-19 After Probiotics

Role: lead

NCT03669029Phase 4Unknown

Optimization of Golimumab Treatment in Ulcerative Colitis

Role: collaborator

NCT02620358Not ApplicableCompleted

Two Opposite Strategies of Weaning From Mechanical Ventilation

Role: collaborator

All 4 trials loaded